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Introduction
In 1961, Sarles et al.1 ﬁrst reported pancreatitis associ-
ated with hypergammaglobulinemia and suggested au-
toimmunity as a pathogenetic mechanism. Since then,
the possible role of autoimmunity in causing chronic
pancreatitis has drawn the attention of several investi-
gators. In 1992, Toki et al.2 reported four cases of an
unusual type of chronic pancreatitis showing diffuse ir-
regular narrowing of the entire main pancreatic duct. In
1995, Yoshida et al.3 summarized the clinical features of
these patients and proposed the concept of autoimmune
pancreatitis (AIP). Since then, many cases of AIP have
been reported in Western countries as well as in Japan.
Many new clinical aspects of AIP have been clariﬁed
during the past 10 years, and AIP has become a distinct
entity recognized worldwide.4–6
After histologically and immunohistochemically ex-
amining various organs and extrapancreatic lesions
of AIP patients, we proposed the existence of a novel
clinicopathological entity, “IgG4-related sclerosing dis-
ease”, and suggested that AIP is not simply pancreatitis
but a pancreatic lesion reﬂecting this systemic disease.7,8
Recently, IgG4-related sclerosing diseases of organs
other than the pancreas have been reported.9–14 Based
on our experience with 32 cases of AIP, this review
focuses on the clinical, laboratory, imaging, and histo-
pathological features of IgG4-related sclerosing disease
as well as AIP. MEDLINE was searched from 1992 to
May 2006 for relevant English-language articles, using
a combination of the terms autoimmune pancreatitis,
sclerosing pancreatitis, sclerosing cholangitis, sclerosing
sialadenitis, retroperitoneal ﬁbrosis, and IgG4. Addi-
tional sources were identiﬁed by scanning the bibliogra-
phies of original and review articles.
Autoimmune pancreatitis (AIP) is a peculiar type of
pancreatitis of presumed autoimmune etiology. Many
new clinical aspects of AIP have been clariﬁed during
the past 10 years, and AIP has become a distinct entity
recognized worldwide. However, its precise patho-
genesis or pathophysiology remains unclear. As AIP
dramatically responds to steroid therapy, accurate diag-
nosis of AIP is necessary to avoid unnecessary surgery.
Characteristic dense lymphoplasmacytic inﬁltration and
ﬁbrosis in the pancreas may prove to be the gold stan-
dard for diagnosis of AIP. However, since it is difﬁcult
to obtain sufﬁcient pancreatic tissue, AIP should be
diagnosed currently based on the characteristic radio-
logical ﬁndings (irregular narrowing of the main pan-
creatic duct and enlargement of the pancreas) in
combination with serological ﬁndings (elevation of se-
rum γ-globulin, IgG, or IgG4, along with the presence
of autoantibodies), clinical ﬁndings (elderly male pre-
ponderance, ﬂuctuating obstructive jaundice without
pain, occasional extrapancreatic lesions, and favorable
response to steroid therapy), and histopathological
ﬁndings (dense inﬁltration of IgG4-positive plasma cells
and T lymphocytes with ﬁbrosis and obliterative phlebi-
tis in various organs). It is apparent that elevation of
serum IgG4 levels and inﬁltration of abundant IgG4-
positive plasma cells into various organs are rather
speciﬁc to AIP patients. We propose a new clinico-
pathological entity, “IgG4-related sclerosing disease”,
and suggest that AIP is a pancreatic lesion reﬂecting this
systemic disease.
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Autoimmune pancreatitis
Concept of AIP
AIP is a unique form of pancreatitis in which autoim-
mune mechanisms are suspected to be involved in the
pathogenesis. AIP has many clinical, radiological, sero-
logical, and histopathological characteristics as follows:
(1) elderly male preponderance; (2) frequent initial
symptom of obstructive jaundice without pain; (3) occa-
sional association with impaired pancreatic endocrine
or exocrine function and various extrapancreatic le-
sions; (4) a favorable response to steroid therapy; (5)
radiological ﬁndings of irregular narrowing of the main
pancreatic duct and enlargement of the pancreas; (6)
serological ﬁndings of elevation of serum γ-globulin,
IgG, or IgG4 levels, along with the presence of some
autoantibodies; and (7) histopathological ﬁndings of
dense lymphoplasmacytic inﬁltration with ﬁbrosis and
obliterative phlebitis in the pancreas.15–17 Typical AIP
shows diffuse changes of the pancreas, but several cases
have shown segmental changes. Localized AIP may
extend progressively to the whole pancreas.18,19 The cur-
rent concept of AIP, including associated extrapan-
creatic lesions, suggests that AIP may be a systemic
disease.7,8,20,21
AIP has been described by various names reﬂecting
different aspects of the entity and each emphasizing the
clinical, radiological, or histological ﬁndings: for ex-
ample, chronic inﬂammatory sclerosis of the pancreas,1
duct-narrowing chronic pancreatitis (DNCP),2
lymphoplasmacytic sclerosing pancreatitis,22  nonalco-
holic duct destructive chronic pancreatitis,23 and idio-
pathic tumefactive chronic pancreatitis.24
Prevalence
AIP is a rare disorder, but its exact incidence is un-
known. In a nationwide survey conducted in Japan, 900
patients with AIP were identiﬁed,25 and the total num-
ber of patients treated for chronic pancreatitis in a year
was estimated as 44700.26 The prevalence rate of AIP
among patients with chronic pancreatitis was 1.95% in
this survey. We encountered 32 patients (8.4%) with
AIP out of 380 patients with chronic pancreatitis clini-
cally diagnosed in our institute. Other reported preva-
lence rates of AIP among chronic pancreatitis cases are
4.6% (21/451) in Japan,27 5.4% (17/315) in Korea,16 and
6.0% (23/383) in Italy.27 In North America, about 2.5%
of pancreatoduodenectomies are performed for AIP
because of a mistaken diagnosis of pancreatic cancer,28
and AIP cases represent between 21%29 and 23%28 of
pancreatoduodenectomies performed for benign condi-
tions. Reported AIP cases are increasing with the grow-
ing awareness of this entity around the world.
Pathogenesis
Serum IgG4 is a subtype of IgG, and its levels are fre-
quently elevated and particularly high in AIP.30,31 Dense
inﬁltration of IgG4-positive plasma cells is seen in vari-
ous organs of AIP patients.7,8,32–34 These results suggest
that IgG4 plays a major role in the pathogenesis of AIP,
although the trigger for the IgG4 elevation or its patho-
genetic role in AIP has not been clearly disclosed.
Antilactoferrin and anti-carbonic anhydrase II (CA-II)
antibodies are frequently detected in AIP patients.35
Therefore, lactoferrin and CA-II have been proposed
as the target antigens, but this has not yet been fully
conﬁrmed. Although the actual effector cells of AIP
have not been clearly delineated, the number of
activated CD4- and CD8-positive T cells bearing HLA-
DR is increased among the peripheral blood lympho-
cytes and in the pancreas of AIP patients.35 It has also
been reported that this disease is closely associated
with the HLA DRB1*0405-DQB1*0401 haplotype,
suggesting that the speciﬁc peptide presented by these
HLA molecules triggers the pathological process of the
autoimmunity.36
Although the many above-mentioned ﬁndings sup-
port an immunologic mechanism of AIP, target antigens
for AIP have not been detected. Its preponderant occur-
rence in elderly men and markedly dramatic response to
oral steroid therapy suggest that the pathogenesis of AIP
might not be by an autoimmune mechanism but by some
other mechanism such as an allergic reaction.
Clinical manifestations
AIP occurs predominantly in elderly men.37 In our se-
ries, the mean age of the patients was 68.3 years (range,
29–83 years) and the male-to-female ratio was 4:1. In a
study in Korea, the mean age was 59.1 years (45–75
years), and the male-to-female ratio was 15:2.16 Patients
rarely show typical features of pancreatitis, and the
major presenting complaint is painless obstructive jaun-
dice due to associated sclerosing cholangitis (65%16 or
86%38  of cases). The jaundice sometimes ﬂuctuates.
Diabetes mellitus, usually type 2, is often (41%39  or
76%16 of cases) observed. In many cases, the diagnoses
of diabetes mellitus and AIP are made simultaneously;
some patients show exacerbation of preexisting diabe-
tes mellitus with the onset of AIP.40 Tanaka et al.41,42
reported that diabetes mellitus with AIP was caused by
T-cell-mediated mechanisms primarily involving islet β-
cells as well as pancreatic duct cells. Pancreatic exocrine
function is frequently impaired, but marked pancreatic
insufﬁciency is uncommon.43 Some patients have other
symptoms related to associated diseases, including
salivary gland swelling due to sclerosing sialadenitis,
hydronephrosis due to retroperitoneal ﬁbrosis, and
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Laboratory ﬁndings
Few patients show marked elevation of serum pancre-
atic enzymes. The patients with biliary lesions show
elevation of serum bilirubin and hepatobiliary enzymes.
Some patients show peripheral eosinophilia or eleva-
tion of serum IgE levels. Hypergammaglobulinemia
(>2.0g/dl) and elevated serum IgG levels (>1800mg/dl)
are detected in 59%–76%45–47 and 53%16–71%45 of AIP
patients, respectively. A diagnostic autoantibody for
AIP has not been detected. Autoantibodies including
antinuclear antibody and rheumatoid factor are present
in 43%–75%39,46,47 and 13%–30%39,46,47 of patients, re-
spectively. Serological ﬁndings may change spontane-
ously during the course of AIP.48 In 2001, Hamano et
al.30 reported that serum IgG4 levels are signiﬁcantly
and speciﬁcally high in AIP patients and are closely
associated with disease activity. According to their re-
port, the use of a cutoff value of 135mg/dl for the serum
IgG4 level resulted in a high rate of accuracy (97%),
sensitivity (95%), and speciﬁcity (97%) for differentiat-
ing AIP from pancreatic cancer. Some AIP patients
show elevated serum IgG4 levels in spite of normal IgG
levels. However, the sensitivity of elevated serum IgG4
levels is 63%–68% in other reports.15,16,49 Elevation of
serum IgG4 levels has been reported in a patient with
pancreatic cancer.50
Radiological ﬁndings
Typical cases of AIP show diffuse enlargement of the
pancreas, the so-called sausage-like appearance, on
computed tomography (CT), ultrasonography (US),
and magnetic resonance image (MRI). On dynamic CT
and MRI, there is delayed enhancement of the swollen
pancreatic parenchyma (Fig. 1a).47,51–53  The affected
pancreatic lesion shows decreased intensity on the T1-
Fig. 1a–f. Radiological ﬁndings of
patients with autoimmune pancre-
atitis.  a  Diffuse enlargement of
the pancreas showing delayed
enhancement on computed to-
mography scan. b A hypointense
capsule-like rim surrounding the
swollen pancreas on a T2-
weighted magnetic resonance im-
age. c Diffuse hypoechoic swollen
pancreas with hyperechoic spots
on US. d Diffuse irregular narrow-
ing of the main pancreatic duct on
endoscopic retrograde pancreato-
graphy. Degree of narrowing var-
ies.  e  Stenosis of the lower bile
duct and segmental narrowing of
the main pancreatic duct of the
pancreatic head on endoscopic
retrograde cholangiopancreato-
graphy. Upstream dilatation of the
distal pancreatic duct is less noted
than with pancreatic cancer. f Af-
ter steroid therapy, both stenosis
of the bile duct and narrowing
of the main pancreatic duct (e)
improved
a
c
e
b
d
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weighted image and increased intensity on the T2-
weighted image compared with the signal intensity in
the liver.51,53,54 Since inﬂammatory and ﬁbrous changes
involve the peripancreatic adipose tissue, a capsule-like
rim surrounding the pancreas, which appears as a low-
density area on CT and as a hypointense area on a T2-
weighted MRI (Fig. 1b), is detected in some cases.47,51–54
US shows an enlarged hypoechoic pancreas with
hyperechoic spots (Fig. 1c).47,51,53 Pancreatic calciﬁcation
or pseudocyst is uncommon. Some cases show a focal
enlargement of the pancreas, similar to that seen
with pancreatic cancer.47,55–57 On endoscopic retrograde
cholangiopancreatography, an irregular, narrow main
pancreatic duct is seen diffusely throughout the pan-
creas in typical cases. The degree of narrowing of the
main pancreatic duct varies in the same patient (Fig.
1d). In some cases, there is segmental narrowing of the
main pancreatic duct, but upstream dilatation of the
distal pancreatic duct is less often noted than in pancre-
atic cancer (Fig. 1e).47,57 In a majority of AIP patients,
both the ventral and dorsal pancreatic ducts are in-
volved, while some patients show the involvement of
only the dorsal pancreatic duct. Patients without in-
volvement of the ventral pancreas tend rarely to present
with obstructive jaundice.58,59 Stenosis of the extrahe-
patic or intrahepatic bile duct is frequently observed
(Fig. 1e). Marked wall thickening of the extrahepatic
bile duct or gallbladder is sometimes detected on US or
endoscopic ultrasonography (EUS).53,60,61  Magnetic
resonance cholangiopancreatography does not ad-
equately show the narrow portion of the main pancre-
atic duct,54 but it can adequately demonstrate stenosis of
the bile duct with dilatation of the upper biliary tract.53
Cervical, hilar, and abdominal lymphadenopathy is
sometimes detected on CT.47,49  On angiography, en-
casement of the peripancreatic arteries and stenosis
of the portal vein are sometimes observed.47,62  F-18
ﬂuorodeoxyglucose (FDG) positron emission tomogra-
phy occasionally demonstrates intense FDG uptake in
the pancreas of AIP patients.63–65
Histopathological and immunohistochemical ﬁndings
In gross appearance, the pancreas in AIP shows ﬁrm
and mass-like enlargement with a thick capsule. The
hallmark of the histological ﬁndings in the pancreas of
AIP patients is dense inﬂammatory cell inﬁltration and
ﬁbrosis in a periductal and interlobular distribution
(Fig. 2a). The inﬂammatory inﬁltrate consists mainly of
lymphocytes and plasma cells with occasional formation
of lymphoid follicles. Perineural inﬁltration is some-
times detected. Fibrosis is usually diffuse and dense, but
loose with stromal edema in some cases. The acinar cells
are then more or less replaced by inﬂammatory cells
and ﬁbrosis, and the lobular architecture of the pan-
creas is almost lost. The pancreatic duct is narrowed by
periductal ﬁbrosis and lymphoplasmacytic inﬁltration
(Fig. 2b). The inﬁltrate is primarily subepithelial, and
the ductal epithelium is usually preserved except for
sparse inﬁltration by lymphocytes. This is appropriately
labeled as lymphoplasmacytic sclerosing pancreatitis.
Another highly characteristic histological ﬁnding is
obliterative phlebitis of the variably sized pancreatic
veins and involvement of the portal vein with
Fig. 2a–c. Histological ﬁndings of
the pancreas of patients with au-
toimmune pancreatitis. a  Promi-
nent periductal and interlobular
ﬁbrosis with a dense lymphop-
lasmacytic inﬁltration and acinar
destruction (hematoxylin-eosin
stain) b Pancreatic duct narrowed
by periductal nonocclusive ﬁbrosis
and lymphoplasmacyticinﬁltration
(elastica-van Gieson stain) c Obli-
terative phlebitis of the pancreatic
veins with prominent lympho-
plasmacytic inﬁltrate and ﬁbrosis
(elastica-van Gieson stain)
a
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lymphoplasmacytic inﬁltrate and proliferation of
ﬁbroblasts in and around the wall of the vein (Fig. 2c).
Such an inﬂammatory process widely and intensely in-
volves the contiguous soft tissue and peripancreatic ret-
roperitoneal tissue.22,32,66–69  Saito et al.70  reported that
histological recovery of the pancreas, including amelio-
ration of the ﬁbrosis and inﬁltration of inﬂammatory
cells and a substantial increase in the number of acinar
cells, was detected in a patient with AIP after steroid
therapy. The wall of the bile duct and gallbladder thick-
ens, histologically showing the same inﬂammatory pro-
cess as that of the pancreas. Regional lymph nodes
are swollen up to 2.0cm in diameter, and show histo-
logically marked follicular hyperplasia and dense
plasmacytic inﬁltration in the paracortical and medul-
lary regions.22,32
These characteristic histological ﬁndings of AIP are
detected during its active phase, and may be a gold
standard for diagnosing AIP.71  However, diagnosing
AIP on the basis of a biopsy or an EUS-guided ﬁne-
needle aspiration biopsy is sometimes difﬁcult, because
of the small sample size.
Immunohistochemically, inﬁltrating inﬂammatory
cells in the pancreas consist of CD4- or CD8-positive T
lymphocytes and IgG4-positive plasma cells (Fig. 3a).
Dense inﬁltration [>30/high-power ﬁeld (hpf)] of IgG4-
positive plasma cells in the pancreas is not observed
in chronic alcoholic pancreatitis or pancreatic cancer.
Inﬁltration of abundant IgG4-positive plasma cells is
also detected in various organs such as the
peripancreatic retroperitoneal tissue, major duodenal
papilla, biliary tract, intrahepatic periportal area (Fig.
3b), salivary glands (Fig. 3c), gastric mucosa, colonic
mucosa, lymph nodes (Fig. 3d), or bone marrow of AIP
patients.7,8,32–34
Diagnostic criteria and differential diagnosis
As it is usually difﬁcult to take specimens from the
pancreas, currently, AIP should be diagnosed on the
basis of combination with clinical, laboratory, and imag-
ing studies. The Japan Pancreas Society has proposed
“Diagnostic Criteria for Autoimmune Pancreatitis,
2002,” containing three items: (1) radiological imaging
showing diffuse enlargement of the pancreas and dif-
fuse irregular narrowing of the main pancreatic duct
(more than one-third the length of the entire pancreas);
(2) laboratory data demonstrating abnormally elevated
levels of serum γ-globulin or IgG, or the presence of
autoantibodies; and (3) histological examination of the
pancreas showing lymphoplasmacytic inﬁltration and
ﬁbrosis. For the diagnosis of AIP, either all of the crite-
ria should be present or criterion 1 together with either
criterion 2 or criterion 3. The presence of the imaging
criterion is essential for diagnosing AIP.27,72 These crite-
ria are based on the minimum consensus features of
AIP to avoid a misdiagnosis pancreatic cancer as far as
possible. However, the accumulation of many AIP cases
has revealed several diagnostic limitations to these
criteria, and revised criteria has been proposed in
2006.73 According to these new criteria, cases showing
localized ductal narrowing over less than one-third
the length of the pancreas can be diagnosed, and sero-
logical ﬁndings showing elevation of the serum IgG4
level is included as one diagnostic factor. Recently,
new diagnostic criteria have been proposed in
Korea74 and the United States75 that include two more
factors: response to steroid therapy and other-organ
involvement.
The most important disease that should be differenti-
ated from AIP is pancreatic cancer. Clinically, patients
with pancreatic cancer and AIP share many features,
such as being elderly, having painless jaundice, develop-
ing new-onset diabetes mellitus, and having elevated
tumor markers.47 Radiologically, focal swelling of the
pancreas, the “double-duct sign,” representing stric-
tures in both the biliary and pancreatic ducts, as well as
angiographic abnormalities can sometimes be seen in
both pancreatic cancer and AIP. As AIP responds dra-
matically to steroid therapy, accurate diagnosis of AIP
can avoid unnecessary laparotomy or pancreatic resec-
tion. Imaging ﬁndings, such as a mass showing delayed
enhancement and a capsule-like rim on dynamic CT or
MRI, and segmental narrowing of the main pancreatic
duct associated with a less-dilated upstream pancreatic
duct, are all useful in differentiating pancreatic cancer
from AIP. Measurement of serum IgG4 levels is a useful
tool for differentiating between the two diseases. We
preliminarily reported that IgG4-immunostaining of bi-
opsy specimens taken from the major duodenal papilla
of AIP patients may support the diagnosis of AIP.76
Although improvement in clinical ﬁndings with steroid
therapy may be useful in the differential diagnosis of
AIP from pancreatic cancer, empiric administration of
steroids should be avoided in order not to misdiagnose
pancreatic cancer as AIP.
It is of uppermost importance to consider the possible
presence of AIP in elderly patients presenting with ob-
structive jaundice and a pancreatic mass.
Treatment and prognosis
Some AIP patients improve spontaneously.77,78 Steroid
therapy is clinically, morphologically, and serologically
effective in AIP patients (Fig. 1e,f). In cases with
obstructive jaundice, endoscopic or percutaneous
transhepatic biliary drainage must be done, and in cases
of diabetes mellitus, glucose levels must be controlled
before steroid therapy is started. The preferred initial
dose of prednisolone is 30–40mg/day, and it is tapered618 T. Kamisawa and A. Okamoto: AIP and IgG4-related sclerosing disease
Fig. 3a–e. IgG4-immunostaining of various organs of patients with autoim-
mune pancreatitis. Dense inﬁltration of IgG4-positive plasma cells was de-
tected in the pancreas (a), periportal area of the liver (b), salivary gland (c),
lymph node (d), and associated retroperitoneal ﬁbrous mass (e)
a
c
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by 5mg every 1–2 weeks. Serological and imaging tests
are performed periodically after commencement of
steroid therapy. Usually, pancreatic size is normalized
within a few weeks, and biliary drainage becomes un-
necessary within 1–2 months. Patients in whom com-
plete radiological improvement is documented can stop
their medication, but most other patients require con-
tinued maintenance therapy with prednisolone 5mg/
day.78 In half of steroid-treated patients, impaired exo-
crine or endocrine function improves.40,43  Some AIP
patients relapse during maintenance therapy or after
stopping steroid medication and should be retreated
with high-dose steroid therapy. The indications for ste-
roid therapy in AIP include obstructive jaundice due to
stenosis of the bile duct or the presence of other associ-
ated systemic diseases, such as retroperitoneal ﬁbrosis.79
Steroid therapy is also effective for sclerosing cholangi-
tis that relapses after surgery.80,81
The long-term prognosis of AIP is not well known. In
our 1- to 22-year follow-up study of AIP patients, the
prognosis was almost always good, except in two pa-
tients who progressed to pancreatic insufﬁciency after
resection.82 It has been reported that recurrent attacks
of AIP result in pancreatic stone formation in some
cases.38
Clinical subtype
Some young patients suffer from AIP. These young AIP
patients are more likely to have abdominal pain and
serum amylase elevation than middle-aged or elderly
patients.83  According to American66  and Italian67  re-
ports, AIP patients with neutrophilic inﬁltration in the
epithelium of the pancreatic duct are younger, more
commonly have inﬂammatory bowel disease, and have a
weaker association with sialadenitis than patients with-
out neutrophilic inﬁltration. AIP might be a heteroge-
neous disease with different clinical aspects, and these
patients with young onset might be another subtype
from the usual AIP as deﬁned in Japan.84 Further inter-
national study of a larger series of clinically relevant
subtypes of AIP is necessary.
Extrapancreatic lesions of AIP
AIP patients frequently have various extrapancreatic
lesions. Since these extrapancreatic lesions show similar
histopathological ﬁndings to those in the pancreas, they
are possibly induced by the same IgG4-related ﬁbro-
inﬂammatory mechanisms as AIP.
Multifocal ﬁbrosclerosis is an uncommon ﬁbroproli-
ferative systemic disorder with multiple manifestations,
including sclerosing cholangitis, ﬁbrosis of the salivary
glands, retroperitoneal ﬁbrosis, Riedel’s thyroiditis, and
ﬁbrotic pseudotumor of the orbit. As histopathological
ﬁndings of these disorders are similar, ﬁbrotic changes
with lymphoplasmacytic inﬁltration and occasional
phlebitis, it has been suggested that they are all inter-
related and probably represent different manifestations
of a common disorder of ﬁbroblastic proliferation.85
Several cases of pancreatic pseudotumor or chronic
pancreatitis associated with multifocal ﬁbrosclerosis
have been reported.86–89  The development of speciﬁc
inﬂammation in extensive organs as well as in the pan-
creas in AIP patients strongly suggests a close relation-
ship between AIP and multifocal ﬁbrosclerosis.32
Sclerosing cholangitis
Sclerosing cholangitis is a heterogeneous disease that
may be associated with choledocholithiasis, biliary tu-
mor, or infection. Sclerosing cholangitis of unknown
origin is called primary sclerosing cholangitis (PSC).
PSC is progressive, despite conservative therapy, and
involves the intra- and extrahepatic bile ducts, resulting
in liver cirrhosis. The effect of steroid therapy is ques-
tionable, and liver transplantation currently provides
the greatest hope for a possible cure. It occurs in
patients in their 30s and 40s and is frequently associated
with inﬂammatory bowel disease.90,91  The pancrea-
togram is not abnormal in most cases.92
Sclerosing cholangitis is frequently associated with
AIP. In many cases, the stenosis is located in the lower
part of the common bile duct (Fig. 1e), but EUS or
intraductal ultrasonography shows wall thickening of
the common bile duct even in the segment in which
abnormalities are not clearly observed with cholangiog-
raphy.60,61 When stenosis is found in the intrahepatic or
the hilar hepatic bile duct, the cholangiographic appear-
ance is very similar to that of PSC.92,93 Sclerosing cholan-
gitis associated with AIP responds dramatically well to
steroid therapy.79,92,93 The histological ﬁndings of scle-
rosing cholangitis associated with AIP include transmu-
ral ﬁbrosis and dense lymphoplasmacytic inﬁltration of
the bile duct wall along with lymphoplasmacytic inﬁltra-
tion and ﬁbrosis in the periportal area of the liver. Com-
pared with PSC, lymphoplasmacytic inﬁltration is more
dense, the degree of ﬁbrosis is less severe, and onion
skin appearance is rarely observed. Dense inﬁltration of
IgG4-positive plasma cells has been detected in the bile
duct wall and the periportal area of patients with AIP,
but it has not been detected in those of patients with
PSC.7,8 Furthermore, elevation of serum IgG4 levels was
not detected in our three patients with PSC. Given the
age at onset, associated diseases, pancreatographic ﬁnd-
ings, response to steroid therapy, prognosis, and IgG4-
related serological and immunohistochemical data,
sclerosing cholangitis associated with AIP should be
differentiated from PSC.92,93  In particular, discrimina-620 T. Kamisawa and A. Okamoto: AIP and IgG4-related sclerosing disease
tion between the two diseases is necessary before mak-
ing therapeutic decisions.
Recently, three cases (in a 50-year-old woman, a 56-
year-old man, and a 77-year-old man) of sclerosing
cholangitis with elevated serum IgG4 levels and dense
inﬁltration of IgG4-positive plasma cells in the bile duct
wall but with no apparent pancreatic lesions compatible
with AIP were reported.9 It is likely that these patients
had an IgG4-related systemic disease with no clinical
manifestations other than sclerosing cholangitis.
Sclerosing sialadenitis (Kuttner’s tumor and
Mikulicz’s disease)
Sclerosing sialadenitis has been referred to as Kuttner’s
tumor, on account of its presentation as a ﬁrm swelling
of the salivary gland that is difﬁcult to differentiate from
a neoplasm.94 Mikulicz’s disease is a unique condition
that involves enlargement of the lachrymal and salivary
glands associated with prominent mononuclear
inﬁltration.95 The pathogenesis of Kuttner’s tumor and
Mikulicz’s disease is unknown.
Some cases of AIP associated with Sjögren’s syn-
drome have been reported.87,96 In our series, swelling
of the salivary glands was detected in 7 of 30 (23%)
patients with AIP, and it was associated with cervical
or mediastinal lymphadenopathy. In these patients, the
salivary glands showed dense inﬁltration of IgG4-
positive plasma cells and ﬁbrosis. However, only a few
(<3/hpf) IgG4-positive plasma cells were seen to
inﬁltrate the salivary glands of 50 patients with
Sjögren’s syndrome, and serum IgG4 levels were not
elevated in ten patients with Sjögren’s syndrome.8 Sali-
vary gland function examined by sialochemistry and
salivary gland scintigraphy was markedly impaired in
many patients with AIP.40,97 Elevation of serum IgG4
levels and dense inﬁltration of IgG4-positive plasma
cells in the salivary glands were usually detected in pa-
tients with sclerosing sialadenitis; furthermore, two of
ﬁve patients with sclerosing sialadenitis developed AIP
during follow-up.8,98 These ﬁndings suggest a close rela-
tionship between AIP and sclerosing sialadenitis. Fur-
thermore, the salivary gland lesion associated with AIP
is different from that of Sjögren’s syndrome.
Two reports dealing with IgG4-related sialadenitis
have been published.10,11 Kitagawa et al.10 reported that
dense inﬁltration of IgG4-positive plasma cells was de-
tected in the salivary glands of 12 patients with scleros-
ing sialadenitis (Kuttner’s tumor), and ﬁve of these
patients (ﬁve men; average age, 64.8 years) had associ-
ated sclerosing lesions in extrasalivary glandular tissue,
such as is the case in AIP, while the remaining seven
patients (three men and four women; average age, 64.4
years) had only salivary gland involvement. Yamamoto
et al.11 reported that in seven patients (two men and ﬁve
women; average age, 66.7 years) with Mikulicz’s dis-
ease, there was a marked elevation of serum IgG4 levels
and dense inﬁltration of IgG4-positive plasma cells
in the lachrymal and salivary glands, and that these
ﬁndings were not were detected in patients with
Sjögren’s syndrome. We experienced a patient with AIP
showing enlargement of bilateral lacrimal glands that
improved after steroid therapy.98 Thus, many cases of
sclerosing sialadenitis, including Kuttner’s tumor and
Mikulicz’s disease, could be salivary gland lesions of
IgG4-related systemic disease.
Retroperitoneal ﬁbrosis
In 1948, Ormond99  described two patients who pre-
sented with anuria caused by bilateral ureteral obstruc-
tion due to envelopment and compression of the ureters
by an inﬂammatory retroperitoneal process identiﬁed as
idiopathic retroperitoneal ﬁbrosis. Idiopathic retroperi-
toneal ﬁbrosis is an uncommon entity of obscure origin
usually conﬁned to the retroperitoneal space and the
pelvic brim.
A total of ten patients (ten men; average age, 63.5
years), including our four patients, have been reported
to have retroperitoneal ﬁbrosis associated with
AIP.46,100–103 In three cases, retroperitoneal ﬁbrosis oc-
curred 10 to 18 months before the onset of AIP. Dense
inﬁltration of IgG4-positive plasma cells and oblitera-
tive phlebitis were found in both the pancreas and retro-
peritoneal ﬁbrous mass (Fig. 3e). These retroperitoneal
ﬁbrotic lesions associated with AIP seem to be retro-
peritoneal lesions of IgG4-related systemic disease. In
all nine of the patients who were treated with steroids,
both the retroperitoneal ﬁbrosis and AIP were resolved.
Recently, a case of a 52-year-old man with retroperito-
neal and mediastinal ﬁbrosis who exhibited elevation of
serum IgG4 levels in the absence of AIP was reported.14
Lymphadenopathy
Little attention has been given to lymph node swelling
in AIP patients. In a study using gallium-67 scintigra-
phy, pulmonary hilar gallium-67 uptake was found in 16
of 24 patients with AIP.104 In our series, abdominal lym-
phadenopathy of up to 2cm in diameter was observed in
ﬁve of eight patients at laparotomy, and cervical or
mediastinal lymphadenopathy of up to 1.5cm in diam-
eter was observed in 7 of 28 patients on CT.8 In all these
cases, the lymphadenopathy disappeared after steroid
therapy. Furthermore, cervical lymphadenopathy was
obvious in ﬁve of six patients with IgG4-related scleros-
ing sialadenitis. Dense inﬁltration of IgG4-positive
plasma cells was detected in all abdominal lymph nodes
(AIP, n = 6; and sclerosing sialadenitis, n = 1) and cervi-
cal lymph nodes (AIP, n = 2; and sclerosing sialadenitis,T. Kamisawa and A. Okamoto: AIP and IgG4-related sclerosing disease 621
n  =  3) (Fig. 3c). However, only a few IgG4-positive
plasma cells were seen to inﬁltrate abdominal lymph
nodes of patients with chronic alcoholic pancreatitis or
pancreatic cancer, or cervical lymph nodes of patients
with Sjögren’s syndrome.8
Sclerosing cholecystitis
In our series, thickening of the gallbladder was detected
on US or CT in 11 of 32 (34%) patients with AIP.
Dense inﬁltration of IgG4-positive plasma cells and
lymphocytes, as well as transmural ﬁbrosis, was de-
tected in the gallbladder wall of six of eight examined
patients.105
Interstitial pneumonia
A 63-year-old man had concurrent interstitial pneumo-
nia and AIP, both of which improved after steroid
therapy. Transbronchial lung biopsy showed dense
inﬁltration of IgG4-positive plasma cells in the alveolar
septum.106  Recently, Hirano et al.107  reported that 4
(four men; average age, 69.5 years) of 30 patients with
AIP had pulmonary involvement, and they showed
good response to steroid therapy.
Tubulointerstitial nephritis
Two cases (in a 64-year-old man108 and a 66-year-old
man109) of tubulointerstitial nephritis associated with
AIP have been reported. Both diseases improved after
steroid therapy. The renal biopsy done in one case
showed IgG4-positive staining along the tubular base-
ment membrane and inﬁltration of IgG4-positive
plasma cells into the tubulointerstitium.
Hepatic inﬂammatory pseudotumor
Hepatic inﬂammatory pseudotumor is a rare benign le-
sion characterized by polyclonal lymphoplasmacytic
inﬁltration with ﬁbrosis and is sometimes misdiagnosed
as primary hepatic malignant tumor. In two reported
cases (a 48-year-old man65 and a 79-year-old man110) of
hepatic inﬂammatory pseudotumor associated with
AIP, the tumor showed dense inﬁltration of IgG4-
positive plasma cells, ﬁbrosis, and obliterative phlebitis.
Both the hepatic inﬂammatory pseudotumor and AIP
improved after steroid therapy. Zen et al.12 found exten-
sive and dense ﬁbrosis with dense inﬁltration of IgG4-
positive plasma cells and lymphocytes, and obliterative
phlebitis was seen in the bile duct lesions of ﬁve patients
(ﬁve men; average age, 65.0 years) with a hepatic
inﬂammatory pseudotumor associated with sclerosing
cholangitis. This suggests that these conditions could be
included in a common disease entity.
Inﬂammatory pseudotumor of the lung
We treated a 63-year-old man who had a concurrent
inﬂammatory pseudotumor of the lung and AIP, both
of which improved after steroid therapy. The resected
lung tumor showed dense inﬁltration of IgG4-positive
plasma cells and lymphocytes intermixed with ﬁbrosis
and obliterative phlebitis. Zen et al.13  reported nine
cases (ﬁve men, four women; average age, 56.8 years)
with an inﬂammatory pseudotumor of the lung that
had the same pathological ﬁndings as those mentioned
above; no cases were associated with AIP, and two
cases were associated with sclerosing sialadenitis or
lymphadenopathy.
Other reported lesions associated with AIP are
pseudotumor of the hypophysis,111  immune throm-
bocytopenic purpura,112,113  autoimmune sensorineural
hearing loss,113 hypothyroidism,114 anosmia,115 and loss
of taste.115
IgG4-related sclerosing disease
By histologically and immunohistochemically examin-
ing various organs of AIP patients, dense inﬁltration of
IgG4-positive plasma cells as well as CD4- or CD8-
positive T lymphocytes and ﬁbrosis have been observed
in the peripancreatic retroperitoneal tissue, bile duct
wall, gallbladder wall, periportal area of the liver, sali-
vary glands, as well as the pancreas of AIP patients.7,8,32
All extrapancreatic lesions associated with AIP such as
sclerosing cholangitis, sclerosing sialadenitis, or retro-
peritoneal ﬁbrosis show inﬁltration of abundant IgG4-
positive plasma cells, but the inﬁltration is not detected
in those of PSC, Sjögren’s syndrome, sialolithiasis,
chronic alcoholic pancreatitis, or pancreatic cancer.
Both pancreatic and extrapancreatic lesions of AIP re-
spond well to steroid therapy, being different from PSC.
We therefore propose the existence of a novel clinico-
pathological entity, an IgG4-related sclerosing disease
incorporating sclerosing pancreatitis, cholangitis,
sialadenitis, and retroperitoneal ﬁbrosis with lymphad-
enopathy. It is histopathologically characterized by
extensive IgG4-positive plasma cell and T-lymphocyte
inﬁltration of various organs. Major clinical manifesta-
tions are apparent in the pancreas, bile duct, salivary
glands, and retroperitoneum, in which tissues ﬁbrosis
with obliterative phlebitis is pathologically induced.
AIP is not simply a pancreatitis, but it is, in fact, a
pancreatic lesion reﬂecting an IgG4-related systemic
disease. Sclerosing cholangitis, sclerosing sialadenitis,
and retroperitoneal ﬁbrosis associated with AIP are dif-
ferent from PSC, Sjögren’s syndrome, and so-called
idiopathic retroperitoneal ﬁbrosis. Most IgG4-related
sclerosing diseases have been found to be associated622 T. Kamisawa and A. Okamoto: AIP and IgG4-related sclerosing disease
with AIP, but IgG4-related sclerosing diseases without
pancreatic involvement have been reported. Some
pseudotumors may be involved in this disease. In some
cases, only one or two organs are clinically involved,
while in others three or four organs are affected (Fig. 4).
The disease occurs predominantly in elderly males, is
frequently associated with lymphadenopathy, and re-
sponds well to steroid therapy. Serum IgG4 levels and
immunostaining with anti-IgG4 antibody are useful in
making the diagnosis.8,116 The precise pathogenesis and
pathophysiology of IgG4-related sclerosing disease re-
main unclear (Table 1).
Since malignant tumors are frequently suspected on
initial presentation, IgG4-related sclerosing disease
should be considered in the differential diagnosis to
avoid unnecessary surgery.
Conclusion
AIP has many clinical, serological, morphological, and
histopathological characteristic features. AIP should be
diagnosed based on combination of these ﬁndings. In an
elderly man presenting with obstructive jaundice and a
pancreatic mass, AIP should be considered as one of the
differential diagnoses to avoid unnecessary surgery.
We proposed a new clinicopathological entity of
IgG4-related sclerosing disease. It is characterized by
extensive IgG4-positive plasma cell and T-lymphocyte
inﬁltration of various organs, and major clinical mani-
festations are apparent in the pancreas, bile duct,
retroperitoneum, and salivary glands, in which tissues
ﬁbrosis with obliterative phlebitis is pathologically in-
duced. Much work needs to be done internationally to
understand the full spectrum of this disease.
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